Dyax, Omeros price follow-ons
Dyax Corp. (NASDAQ:DYAX) and Omeros Corp. (NASDAQ:OMER) both priced follow-ons on Friday. Dyax raised $74 million through the sale of 8 million shares at $9.25 in a follow-on underwritten by Jefferies; Cowen; Wedbush PacGrow; Needham; and Oppenheimer. Dyax proposed the offering late Thursday, when its share price was $10.15. The company markets Kalbitor ecallantide for hereditary angioedema (HAE) in the U.S.
Omeros raised $35 million through the sale of 3 million shares at $11.50 in a follow-on underwritten by Cowen; Wedbush PacGrow; Needham; Maxim; WBB Securities; and MLV. Omeros proposed the follow-on late Thursday, when its share price was $12.30. The company's Omidria ( OMS302) is under review in the U.S. and EU to maintain intraoperative mydriasis, prevent intraoperative miosis and reduce postoperative ocular pain in patients undergoing intraocular lens replacement surgery. OMS302 is a combination of the anti-inflammatory agent ketorolac and the pupil dilating agent phenylephrine. ...